Raymond James Financial
AVTX icon

Raymond James Financial’s Avalo Therapeutics AVTX Stock Holding History

Raymond James Financial’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$5 – 5107
2025
Q2 		$5 Buy
+1
New +$5 ﹤0.01% 6958

Other funds holding AVTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Raymond James Financial's AVTX Position: Q3 2025 in Review

Raymond James Financial sold out of Avalo Therapeutics (AVTX) in Q3 2025, closing a stake of 1 share — an estimated $5 sold.

Raymond James Financial first reported a position in AVTX in Q2 2025 and held it in 1 quarter. The position peaked at $5 in Q2 2025. 66 funds tracked by Wall St. Rank hold AVTX as of Q3 2025.

  • Raymond James Financial reported no remaining Avalo Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1 Avalo Therapeutics share in Q3 2025, an estimated $5.
  • Raymond James Financial first reported a position in Avalo Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Avalo Therapeutics position peaked at $5 in Q2 2025.
  • 66 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.